SG Americas Securities
EPIX

SG Americas Securities’s ESSA Pharma EPIX Stock Holding History

SG Americas Securities’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,093
Closed -$631K – 3841
2021
Q2 		$631K Buy
22,093
+2,804
+15% +$81.5K ﹤0.01% 1835
2021
Q1 		$560K Buy
+19,289
New +$448K ﹤0.01% 1946

Other funds holding EPIX

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

SG Americas Securities's EPIX Position: Q3 2021 in Review

SG Americas Securities sold out of ESSA Pharma (EPIX) in Q3 2021, closing a stake of 22,093 shares — an estimated $631K sold.

SG Americas Securities first reported a position in EPIX in Q1 2021 and held it in 2 quarters. The position peaked at $631K in Q2 2021. 75 funds tracked by Wall St. Rank hold EPIX as of Q3 2021.

  • SG Americas Securities reported no remaining ESSA Pharma position as of Q3 2021 after selling out during the quarter.
  • SG Americas Securities sold 22,093 ESSA Pharma shares in Q3 2021, an estimated $631K.
  • SG Americas Securities first reported a position in ESSA Pharma in Q1 2021 and held it in 2 quarters.
  • SG Americas Securities's ESSA Pharma position peaked at $631K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2021.

Based on SG Americas Securities's 13F filing for Q3 2021, filed 1 Nov 2021.